Johnson & Johnson (JNJ – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Lee ...

Analyst Tim Anderson of Bank of America Securities reiterated a Hold rating on Johnson & Johnson (JNJ – Research Report), reducing the ...

Intra-Cellular Therapies makes Caplyta, a once-daily pill for adults with schizophrenia and bipolar-related depression ...

Johnson & Johnson is a holding company ... and MedTech. The Consumer Health segment includes products focused on personal healthcare used in the Skin Health/Beauty, Over-the-Counter medicines ...

Johnson & Johnson “should have known that the J&J Products contained harmful, deleterious, carcinogenic and inherently dangerous asbestos dust and fibers” and the products reportedly did not ...

Reviewed by Thomas Brock Fact checked by Vikki Velasquez Johnson & Johnson is one of the largest and most successful ...

Her diagnosis was "a direct and proximate result of Ms Cartwright's inhalation and ingestion of asbestos contained within the J&J products," it alleged. Johnson & Johnson has denied the ...

In 2021, Johnson & Johnson unveiled a plan to spin off its consumer products division to focus on pharmaceuticals and medical technology. The company completed the Kenvue spinoff to shareholders ...

Both these factors can be tied in part to J&J’s strong presence in the consumer ... products is a strong pharmaceutical backbone that has emerged over the company’s long and varied history ...